Bai, Xilong
Chen, Tingwei
Li, Yuqi
Ge, Xiaofan
Qiu, Caie
Gou, Huili
Wei, Sili
Liu, Tingting
Yang, Wei
Yang, Liting
Liang, Yingmin
Jia, Zhansheng
Lv, Liangshan
Li, Tianqing
Funding for this research was provided by:
National Key Research and Development Program of China (2022YFA1103100)
Natural Science Foundation of Yunnan Province (202102AA100007, 202102AA100053, 202001BC070001, YNWR-YLXZ-2020-015)
Spring City Plan the High-level Talent Promotion and Training Project of Kunming
Key Research and Development Projects of Shaanxi Province (2021SF-104)
Xi'an Talent Program Young Talents
Foundation for Advancement of International Medical Education and Research (2020QN001)
Article History
Received: 18 April 2023
Accepted: 29 November 2023
First Online: 18 December 2023
Declarations
:
: All umbilical cord and PBMCs samples were taken after informed and written consent, and the study was approved by the Ethics Committee of Xi'an Gaoxin Hospital (Title is the study of heterogeneity of clinical-grade human umbilical cord, placenta, and adipose-derived mesenchymal stromal cells. Approval number is GXYYEC-KTSB-2020-03-01. Date of approval is March 20, 2020.). The procedures for mice model generation and WJ-MSCs injection were approved by the Institutional Animal Care and Use Committee of Kunming University of Science and Technology (Title is therapeutic value and application evaluation of mesenchymal stromal cells in a rodent model of autoimmune hepatitis. Approval number is PZWH-K2022-0014. Date of approval is Jun 16, 2022.) and were performed in accordance with the Guide for the Care and Use of Laboratory Animals. The study adhered to the Declaration of Helsinki.
: Not applicable.
: The authors X. B., X. G., C. Q., H. G., S. W., T. L., W. Y., L. Y., and T. L. are employed by Xi'an ChaoYue Stem Cell Co., Ltd. and hold no stocks of the company. The other authors declare that they have no competing interests.